Philadelphia Chromosome Positive Completed Phase 4 Trials for Nilotinib (DB04868)

Also known as: Philadelphia chromosome positive

IndicationStatusPhase
DBCOND0046287 (Philadelphia Chromosome Positive)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01043874Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal ResponseTreatment